Table 2 Frequency of systemic antifungal strategies used, according to transplant anteriority, neutropenic phase, and GVHD status
alloHSCT timing | Neutropenia | GVHDa | Total | |||||
|---|---|---|---|---|---|---|---|---|
≤ 2 months (n = 95) | > 2–<6 months (n = 28) | ≥ 6 months (n = 24) | No (n = 83) | Yes (n = 64) | – (n = 100) | + (n = 47) | (N = 147) | |
Not treated with systemic antifungals | 10 (11) | 11 (39) | 7 (29) | 15 (18) | 13 (20) | 17 (17) | 11 (23) | 28 (19) |
Treated with systemic antifungals | 85 (89) | 17 (61) | 17 (71) | 68 (82) | 51 (80) | 83 (83) | 36 (77) | 119 (81) |
Prophylaxisb | 68 (80) | 14 (82) | 13 (76) | 57 (84) | 38 (75) | 68 (82) | 27 (75) | 95 (80) |
Empiric strategyb | 11 (13) | 1 (6) | 1 (6) | 4 (6) | 9 (18) | 10 (12) | 3 (8) | 13 (9) |
Pre-emptive or curative strategyb | 6 (7) | 2 (12) | 3 (18) | 7 (10) | 4 (8) | 5 (6) | 6 (17) | 11 (7) |